Zoe E. Quandt

Zoe E. Quandt

Endocrinology

400 Parnassus Ave.
Suite A-550
San Francisco, CA 94143

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis-Reply.

Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis-Reply.

Journal: JAMA oncology

Published: June 04, 2026

AEGIS reveals epitope- and clone-resolved convergence of CNS B and T cell autoreactivity in ROHHAD.

AEGIS reveals epitope- and clone-resolved convergence of CNS B and T cell autoreactivity in ROHHAD.

Journal: bioRxiv : the preprint server for biology

Published: May 25, 2026

Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.

Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.

Journal: Research square

Published: February 23, 2026

Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.

Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.

Journal: Research square

Published: February 23, 2026

Immune Checkpoint Inhibitor-Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 Agents.

Immune Checkpoint Inhibitor-Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 Agents.

Journal: JAMA oncology

Published: December 26, 2025

Accuracy of glutamic acid decarboxylase antibodies for the identification of adult-onset type 1 diabetes mellitus: a systematic review and meta-analysis.

Accuracy of glutamic acid decarboxylase antibodies for the identification of adult-onset type 1 diabetes mellitus: a systematic review and meta-analysis.

Journal: Frontiers in endocrinology

Published: December 20, 2025

A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer.

A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 23, 2025

Glucocorticoids to Manage Cytokine Release Syndrome During Teplizumab Therapy for New-Onset Type 1 Diabetes.

Glucocorticoids to Manage Cytokine Release Syndrome During Teplizumab Therapy for New-Onset Type 1 Diabetes.

Journal: Diabetes care

Published: October 10, 2025

GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization.

GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization.

Journal: The Journal of clinical endocrinology and metabolism

Published: September 10, 2025

Impact of baseline medications on real-world overall survival in immune checkpoint inhibitor-treated patients with cancer in the RADIOHEAD cohort.

Impact of baseline medications on real-world overall survival in immune checkpoint inhibitor-treated patients with cancer in the RADIOHEAD cohort.

Journal: Med (New York, N.Y.)

Published: September 09, 2025

irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets.

irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets.

Journal: EBioMedicine

Published: August 16, 2025

Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.

Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.

Journal: Journal for immunotherapy of cancer

Published: July 21, 2025

Showing 1-12 of 51

Last Updated: 09/26/2026